The use of intermediate‐acting neutral protamine Hagedorn insulin decreased in prevalent users through follow‐up, from 7.6% to 2.4% in T1D and 17% to 4.1% in T2D. The gene discussed is INS; the disease is type 1 diabetes mellitus.